

Announcement Summary

Entity name

ONCOSIL MEDICAL LTD

Announcement Type

New announcement

Date of this announcement

20/3/2024

The Proposed issue is:

A standard pro rata issue (including non-renounceable or renounceable)

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	OPTION EXPIRING 30-JUN-2025 EX \$0.009	1,129,413,846
OSL	ORDINARY FULLY PAID	1,129,413,846
OSLO	OPTION EXPIRING 30-APR-2027	564,706,923

Ex date

26/3/2024

+Record date

27/3/2024

Offer closing date

24/4/2024

Issue date

2/5/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

ONCOSIL MEDICAL LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ACN

113824141

1.3 ASX issuer code

OSL

1.4 The announcement is New announcement

1.5 Date of this announcement

20/3/2024

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

1.6a The proposed standard +pro rata issue is:

+ Non-renounceable



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

No

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

OSL : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class Will the proposed issue of this +security include an offer of attaching +securities? Yes If the entity has quoted company options, do the terms entitle option holders to participate on exercise? No

Details of +securities proposed to be issued

ASX +security code and description

OSL : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)The quantity of additional +securities
to be issuedFor a given quantity of +securities
held12



What will be done with fractional entitlements?	Maximum number of +securities proposed to be issued (subject to rounding)
Fractions rounded up to the next whole number	1,129,413,846

Offer price details for retail security holders

In what currency will the offer be made?	What is the offer price per +security for the retail offer?
AUD - Australian Dollar	AUD 0.00500

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?

Yes

Describe the limits on over-subscription

Additional Securities will only be available where the total number of New Shares the subject of all Applications received under the Entitlement Offer is less than the aggregate available under the Entitlement Offer. Additional Securities will only be issued at the Board's discretion - there is no guarantee that the Board will issue any Additional Securities under the Top-Up Facility.

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

The Company reserves the right to scale back any applications for Additional Securities in its absolute and sole discretion. When determining the amount (if any) by which to scale back an application, the Company may take into account a number of factors, including the size of an Applicant's shareholding, the extent to which an Applicant has sold or bought Shares in the Company before and after both the announcement of the Offers and the Record Date, as well as when the application was made.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Attaching +Security

Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)? New class Existing class

Attaching +Security - New class (+securities in a class that is not yet guoted or recorded by ASX)

Details of attaching +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)



ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?	Will the entity be seeking quotation of the 'new' class of +securities on ASX?	
No	No	
ASX +security code	+Security description	
New class-code to be confirmed	OPTION EXPIRING 30-JUN-2025 EX \$0.009	
+Security type		
Options		
Offer ratio (ratio of attaching securities at which the new	+securities will be issued)	
The quantity of attaching +securities to be issued	For a given quantity of the new +securities issued	
1	1	
What will be done with fractional entitlements?	ximum number of +securities proposed to be issued	
Fractions rounded up to the next whole number	(subject to rounding)	
	1,129,413,846	
Offer price details for retail security holders		
In what currency will the offer be made?	What is the offer price per +security for the retail offer?	
	AUD 0.00000	
AUD - Australian Dollar		

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? Yes

Describe the limits on over-subscription

Additional Securities will only be available where the total number of New Shares the subject of all Applications received under the Entitlement Offer is less than the aggregate available under the Entitlement Offer. Additional Securities will only be issued at the Board's discretion - there is no guarantee that the Board will issue any Additional Securities under the Top-Up Facility.

Will a scale back be applied if the offer is over-subscribed? Yes

Describe the scale back arrangements

The Company reserves the right to scale back any applications for Additional Securities in its absolute and sole discretion. When determining the amount (if any) by which to scale back an application, the Company may take into account a number of factors, including the size of an Applicant's shareholding, the extent to which an Applicant has sold or bought Shares in the Company before and after both the announcement of the Offers and the Record Date, as well as when the application was made.

Will all the +securities issued in this class rank equally in all respects from their issue date? $\ensuremath{\mathsf{Yes}}$



Options details

+Security currency

AUD - Australian Dollar

Exercise price	Expiry date
AUD 0.0090	30/6/2025

Details of the type of +security that will be issued if the option is exercised

OSL : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One OSL fully paid ordinary share

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Attaching +Security - Existing class (additional +securities in a class that is already quoted or recorded by ASX)

Details of attaching +securities proposed to be issued ASX +security code and description

OSLO : OPTION EXPIRING 30-APR-2027

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio of attaching securities at which the new +securities will be issued)

The quantity of attaching +securities to be issued	For a given quantity of the new +securities issued	
1	2	
What will be done with fractional entitlements?	Maximum number of +securities proposed to be issued	
Fractions rounded up to the next whole number	(subject to rounding)	
	564,706,923	
Offer price details for retail security holders		
In what currency will the offer be made?	What is the offer price per +security for the retail offer?	
	AUD 0.00000	
AUD - Australian Dollar		

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? Yes

Describe the limits on over-subscription

Additional Securities will only be available where the total number of New Shares the subject of all Applications received under the Entitlement Offer is less than the aggregate available under the Entitlement Offer. Additional Securities will only be issued at the Board's discretion - there is no guarantee that the Board will issue any Additional Securities under the Top-Up Facility.

Will a scale back be applied if the offer is over-subscribed? Yes

Describe the scale back arrangements

The Company reserves the right to scale back any applications for Additional Securities in its absolute and sole discretion. When determining the amount (if any) by which to scale back an application, the Company may take into account a number of factors, including the size of an Applicant's shareholding, the extent to which an Applicant has sold or bought Shares in the Company before and after both the announcement of the Offers and the Record Date, as well as when the application was made.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 3C - Timetable

3C.1 +Record date

27/3/2024

3C.2 Ex date

26/3/2024

3C.4 Record date

27/3/2024

3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue

3/4/2024

3C.6 Offer closing date

24/4/2024

3C.7 Last day to extend the offer closing date

19/4/2024

3C.9 Trading in new +securities commences on a deferred settlement basis 26/4/2024

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

2/5/2024



3C.12 Date trading starts on a normal T+2 basis

3/5/2024

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

7/5/2024

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer?

Yes

3E.1a Who is the lead manager/broker?

Forrest Capital Pty Ltd and McFarlane Cameron Pty Ltd have been appointed as Joint Lead Managers

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% (exclusive of GST) on all monies raised via the rights issue

3E.2 Is the proposed offer to be underwritten?

Yes

3E.2a Who are the underwriter(s)?

Forrest Capital Pty Ltd and McFarlane Cameron Pty Ltd

3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?

Up to a maximum of \$2 million

3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?

No separate underwriting fee in addition to the 6% plus GST as Joint Lead Managers on any funds raised under the Capital Raising

3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated

The underwriting is an unconditional and irrevocable joint and several obligation and there are no termination provisions

3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer? No

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Proceeds from the Entitlement Offer will be used primarily to support commercialisation and accreditation from regulatory bodies for the OncoSil device and to fund clinical trials.

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful? No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed



issue

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

No

3F.6 URL on the entity's website where investors can download information about the proposed issue

www.oncosil.com/investors/

3F.7 Any other information the entity wishes to provide about the proposed issue

Refer Placement and Entitlement Offer announcement dated 20 March 2024

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)? Yes

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a +disclosure document or +PDS for the +securities proposed to be issued